Drug Trial Radar · NCT03030612
A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Last checked: Nov 19, 2026Latest source record: Aug 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Dec 2016
Primary completion
Aug 2022
Study completion Aug 2022
Sponsor
- Lead sponsor
- OncoVerity, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- argenx; Janssen Research & Development, LLC
- First posted
- Jan 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the maximum tolerated dose (MTD) of ARGX-110 and/or the recommended Phase II dose (RP2D) in combination with a standard dose of azacytidine (AZA) in Phase 1; and to evaluate efficacy of ARGX-110 when administered at a RP2D level established in Phase I in combination with a standard dose of AZA (proof-of concept) by evaluating overall response rate (ORR) in Phase 2.
Conditions
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
Interventions
ARGX-110Drug
ARGX-110 will be administered intravenously.
AZADrug
AZA will be administered subcutaneously/intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants with Dose Limiting Toxicity (DLT)Time frame: Up to 3.6 years
- Phase 2: Overall Response Rate (ORR)Time frame: Up to 3.6 years
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Marseille, France
Site not named
Paris, France
Site not named
Pierre-Bénite, France
Site not named
Toulouse, France
Site not named
Aarau, Switzerland
Site not named
Bern, Switzerland
Site not named
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.